Article

Johns Hopkins licenses rights to retinal therapy

Laurel, MD-The Johns Hopkins University Applied Physics Laboratory(APL) has licensed the international rights to Novadaq Technologies fora patented method for diagnosing and treating age-related macular degeneration(AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
(Image credit: AdobeStock/upnowgraphics) Ophthalmology Times: AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium
June 9th 2025

AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

University of Colorado Anschutz Medical Campus Ophthalmology Department receives $40 million gift
June 9th 2025

University of Colorado Anschutz Medical Campus Ophthalmology Department receives $40 million gift

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Exploring the future of AI in ophthalmology with Mark Daly
June 8th 2025

Exploring the future of AI in ophthalmology with Mark Daly

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis
June 8th 2025

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis

© 2025 MJH Life Sciences

All rights reserved.